A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes
A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 248 participants.
Also called NCT01474083
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose basic science
- Phase
- Phase 1/2
- Enrolled
- 248 participants
- Sponsor
- Registry
-
NCT01474083
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01474083. Randomized; quadruple masking; primary purpose basic science. Start 2011-11 (registry gives no type); primary completion 2012-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- GK1-399 (formerly TTP399)
- Intervention (Drug)
- GK1-399 (formerly TTP399)
- Intervention (Drug)
- GK1-399 (formerly TTP399)
- Intervention (Drug)
- Placebo
- Lead sponsor
- vTv Therapeutics
Record details
- Record id
cardio:ct-nct01474083- Content hash
6396aa6a86c293fac98d9967a19f353b12611bf72eb8ea6ea100116e7307cdf9